Though nothing has been published to date implicating PTEN in promoting immune escape in HCC, PTEN is altered in 7% of human HCC patients (28) making this pathway an appealing option for targeted therapies; however, future studies are needed to demonstrate whether or not tumor-intrinsic loss of PTEN leads to immune escape in HCC. This evidence concerns the gene PTEN and neoplasm.